Technical Analysis for TROV - TrovaGene, Inc.

Grade Last Price % Change Price Change
grade F 1.87 -8.78% -0.18
TROV closed down 8.78 percent on Friday, September 13, 2019, on 64 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical TROV trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
20 DMA Resistance Bearish -8.78%
50 DMA Support Bullish -8.78%
MACD Bullish Signal Line Cross Bullish -8.78%
Pocket Pivot Bullish Swing Setup -8.78%
Wide Bands Range Expansion -8.78%
Up 3 Days in a Row Strength -8.78%
Oversold Stochastic Weakness -8.78%

Older signals for TROV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company's urine-based testing platform facilitates to enhance the management of cancer care and women's healthcare. Its proprietary urine-based molecular diagnostic tests are used to detect transrenal DNA and RNA that are cell-free nucleic acids found in urine. The company's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. In addition, it owns rights to nucleophosmin-1, an informative biomarker for acute myeloid leukemia and mutations in the SF3B1 gene that are to be associated with chemotherapy response in chronic lymphocytic leukemia patients. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene Inc. in January 2010. Trovagene Inc. was founded in 1999 and is headquartered in San Diego, California.
Medicine Biotechnology Cancer Healthcare Clinical Medicine Infectious Diseases Oncology Chemotherapy Tumor Acute Myeloid Leukemia Diagnostic Tests Leukemia Chronic Lymphocytic Leukemia Transplantation Biomarkers Cancer Care
Is TROV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.64
52 Week Low 1.3
Average Volume 342,985
200-Day Moving Average 3.0679
50-Day Moving Average 1.9854
20-Day Moving Average 2.099
10-Day Moving Average 1.915
Average True Range 0.1963
ADX 20.46
+DI 26.1166
-DI 18.8003
Chandelier Exit (Long, 3 ATRs ) 2.5311
Chandelier Exit (Short, 3 ATRs ) 1.8889
Upper Bollinger Band 2.7609
Lower Bollinger Band 1.4371
Percent B (%b) 0.33
BandWidth 63.068128
MACD Line -0.028
MACD Signal Line -0.0244
MACD Histogram -0.0036
Fundamentals Value
Market Cap 69.69 Million
Num Shares 37.3 Million
EPS -1.25
Price-to-Earnings (P/E) Ratio -1.49
Price-to-Sales 76.85
Price-to-Book 6.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.14
Resistance 3 (R3) 2.16 2.10 2.10
Resistance 2 (R2) 2.10 2.03 2.09 2.08
Resistance 1 (R1) 1.98 1.99 1.95 1.96 2.06
Pivot Point 1.92 1.92 1.90 1.91 1.92
Support 1 (S1) 1.80 1.85 1.77 1.78 1.68
Support 2 (S2) 1.74 1.81 1.73 1.66
Support 3 (S3) 1.62 1.74 1.65
Support 4 (S4) 1.60